Abstracts Archive - Page 179 of 2607 - ACR Meeting Abstracts

Abstract Number: 1326 • ACR Convergence 2025
Association Between Physical Function and Nutritional Status in Rheumatoid Arthritis Patients
Yasumori Sobue¹, Mochihito Suzuki², Yoshifumi Ohashi³, Shuji Asai² and Shiro Imagama², ¹Sobue Orthopedic Clinic Yatomi, Aichi, Japan, ²Nagoya University Graduate School of Medicine, Nagoya, Japan, ³Aichi Medical University, Graduate School of Medicine, Aichi, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory disease that primarily affects the joints but also has substantial implications for physical function. Persistent inflammation may…
Abstract Number: 1306 • ACR Convergence 2025
Systematic Literature Review of Digital Sleep Outcomes and Endpoints Used to Assess Rheumatoid Arthritis
Anna fishbein¹, Rachel Lawson², Veleka Allen¹, Sophie Wilhelm¹, Tracy Zhang³, Leanne Williams¹, Karen Chandross¹, Godhuli Chatterjee⁴, Markus Kohlmann⁵ and Jeffrey Curtis⁶, ¹Sanofi, Morristown, NJ, ²Sanofi, Earley, United Kingdom, ³Sanofi, Waltham, MA, ⁴Sanofi Healthcare India Private Limited, Mumbai, Maharashtra, India, ⁵Sanofi, Frankfurt, Germany, ⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Sleep disturbances are prevalent among patients with rheumatoid arthritis (RA), posing a substantial burden to patients and are intricately linked to disease activity and…
Abstract Number: 1242 • ACR Convergence 2025
Relax the Body: Dual-Agent Nighttime Therapy for Fibromyalgia: Symptom Reduction Using Tricyclic Antidepressants and Muscle Relaxants
Robert Katz¹, Alexandra Katz Small², Edwin Moore³ and Seth Adler⁴, ¹Rush University Medical Center, Chicago, IL, ²Rheumatology Associates, CHICAGO, IL, ³University of Illinois Urbana Champaign, CHICAGO, IL, ⁴Rush University Medical Center, Chicago, IL
Background/Purpose: Fibromyalgia (FM) is a multifaceted disorder defined by chronic widespread pain, sleep disruption, fatigue, and cognitive difficulties. Although the predominant theory behind FM pathogenesis…
Abstract Number: 1311 • ACR Convergence 2025
Decade-Based Trends in First Remission Among Rheumatoid Arthritis Patients: A Population-Based Study
Georges El Hasbani¹, Roslin George², Anne Shurtz¹, Cynthia Crowson³ and Elena myasoedova², ¹Mayo Clinic, Rochester, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Stewartvillle, MN
Background/Purpose: Early and aggressive treatment of rheumatoid arthritis (RA) has been linked to improved remission rates, but achieving early and sustained remission remains a challenging…
Abstract Number: 1222 • ACR Convergence 2025
Efficacy of Fasinumab, An Anti-Nerve Growth Factor Monoclonal Antibody, in Managing Chronic Musculoskeletal Pain: A Systematic Review and Meta-Analysis
Ahmed Abouelella¹, Mohammad Alhasan², Ahmed Hamoudah³, Ayman Ibrahim⁴, Ola O.A. Abuzied⁵, Mansoor Al-Tamimi⁶ and Muhammed Elhadi⁷, ¹Faculty of Medicine, Benha University, Benha, Al Qalyubiyah, Egypt, ²Health Education England Internal Medicine Training ( Cambridge), Cambridge, United Kingdom, ³Libyan International University, Sarasota, FL, ⁴University of Gezira, Medina, Saudi Arabia, ⁵University of Khartoum, Khartoum, Sudan, ⁶Faculty of Medicine, Cairo University, Cairo, Egypt, ⁷University of Tripoli, Huston, TX
Background/Purpose: Chronic musculoskeletal pain can be a significant source of disability and poor quality of life in adults. Many patients do not achieve adequate relief…
Abstract Number: 1126 • ACR Convergence 2025
Clinical Impact of Signs of Calcium Pyrophosphate Deposition Disease (CPPD) on Radiographs of Hands and Wrists in a Real-World Cohort of Patients with Early Rheumatoid Arthritis
Coralie Tremblay¹, Nathalie Carrier², Hugues Allard-Chamard³, Javier Marrugo⁴, Sophie Roux⁴, Gilles Boire⁵ and Ariel Masetto⁴, ¹Université de Sherbrooke, Division of Rheumatology, Department of Medicine and Health Sciences, Sherbrooke, Canada, and Centre intégré universitaire de santé et de services sociaux de l’Estrie – Centre hospitalier universitaire de Sherbrooke (CIUSSS de l’Estrie – CHUS), Sherbrooke, Canada, Saint-Augustin-de-Desmaures, QC, Canada, ²Centre integré universitaire de santé et de services sociaux de l’Estrie – Centre hospitalier universitaire de Sherbrooke (CIUSSS de l’Estrie-CHUS), Sherbrooke, Canada, ³Université de Sherbrooke, Sherbrooke, Canada, ⁴Université de Sherbrooke, Division of Rheumatology, Department of Medicine and Health Sciences, Sherbrooke, Canada, and Centre intégré universitaire de santé et de services sociaux de l’Estrie – Centre hospitalier universitaire de Sherbrooke (CIUSSS de l’Estrie – CHUS), Sherbrooke, Canada, Sherbrooke, Canada, ⁵Retired, Sherbrooke, QC, Canada
Background/Purpose: Calcium pyrophosphate deposition disease (CPPD) is a common cause of arthropathy over the age of 60. It can also manifest as a chronic polyarticular…
Abstract Number: 1070 • ACR Convergence 2025
Cervical Cancer and HPV Screening in Women with Lupus vs Healthy Control Group: A Retrospective Study at a Tertiary Referral Center
Mahnoor Javed¹, Deepak Jagannath², Alma Aveytia Camacho³, Alwyn Mathew³, Konrad Harms³, Soudabeh Daliri³ and Myriam Guevara⁴, ¹Houston Methodist, Richmond, TX, ²Houston Methodist Hospital, Sugar Land, TX, ³Houston Methodist, Houston, ⁴Houston Methodist, Houston, TX
Background/Purpose: Women with SLE are at an increased risk of developing cervical cancer, primarily by human papillomavirus (HPV) and immunosuppression. This elevated risk has been…
Abstract Number: 1319 • ACR Convergence 2025
The Association of Rheumatoid Arthritis in Patients with Vitiligo: Systematic Review and Meta-Analysis
Nattanicha Chaisrimaneepan¹, thunyaporn Khoruamklang², Pitchaporn Yingchoncharoen³, Tulaton Sodsri⁴ and Miriam Paz³, ¹Texas Tech University Health Sciences Center, Lubbock, TX, ²²Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, bangkok, Thailand, ³Texas Tech University Health Sciences Center, Lubbock, ⁴Department of Medicine, Texas Tech University Health Sciences Center, Bangkok, Thailand
Background/Purpose: Vitiligo is associated with many autoimmune diseases, but its association with rheumatic disease has not been well-defined. Therefore, we conducted a systematic review and…
Abstract Number: 1253 • ACR Convergence 2025
Patient Reported Outcome Measures: Assessing Resident Physician Acceptance of the Routine Assessment of Patient Index Data 3 Survey and its Impact on Physician-Patient Relationship
Nisha Sapkota¹, Chana Birnbaum², Henna Levitansky², Yevheniia Andriushchenko², Saadia Malik², Melissa Andrade², Sarang Choi² and Sima Terebelo², ¹Interfaith Medical Center, One Broolyn Health, Brooklyn, NY, ²Brookdale Hospital Medical Center, One Brooklyn Health, Brooklyn
Background/Purpose: When treating patients with rheumatological conditions, building a strong physician-patient relationship plays an important role in determining disease outcomes. The Routine Assessment of Patient…
Abstract Number: 1198 • ACR Convergence 2025
Induction of stable, GC-free remission in patients with severe, therapy-refractory anti-synthetase syndrome after using the bispecific CD19xCD3 T cell engager blinatumomab
Christina Duesing¹, Ayla Nadja Stuetz², Andrea-Hermina Györfi³, Laura-Marie Lahu⁴, Franca Sophie Deicher⁵, Gamal Chehab⁶, Jutta Richter⁷, Marie Celine van Saan⁸, Bilgesu Safak Tümerdem², Alexandru-Emil Matei⁹, Bjoern Buehring¹⁰, Ricardo Grieshaber-Bouyer¹¹, Melanie Hagen¹², Georg Schett¹³, Wolfgang Merkt¹⁴ and Jörg Distler¹⁵, ¹Klinik für Rheumatologie, Düsseldorf, Germany, ²Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Nordrhein-Westfalen, Germany, ³Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany, ⁴Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Germany, ⁵Uniklinik Düsseldorf, Düsseldorf, Germany, ⁶Policlinic of Rheumatology and Hiller Research Unit Rheumatology, Heinrich-Heine-University, Düsseldorf, Germany, ⁷Clinic for Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Duesseldorf, Germany, Düsseldorf, Germany, ⁸Department of Rheumatology, University Hospital Duesseldorf, Medical Faculty of Heinrich Heine University, Duesseldorf, ⁹Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany, ¹⁰Bergisches Rheuma-Zentrum, Wuppertal, Germany, ¹¹University Hospital Erlangen, Erlangen, Germany, ¹²Friedrich-Alexander-University Erlangen-Nuremberg, Department of Internal Medicine ³ - Rheumatology and Immunology, Erlangen, Germany, ¹³Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ¹⁴University Hospital Düsseldorf, Düsseldorf, Germany, ¹⁵University Hospital Duesseldorf and HHU, Duesseldorf, Germany
Background/Purpose: Treatment of anti-synthetase syndrome (ASyS) presents clinical challenges: myositis can lead to permanent disability and severe organ involvement is life-threatening.Methods: We treated three patients…
Abstract Number: 1233 • ACR Convergence 2025
Synovial Joint Transcriptomic Differences in Individuals with Knee Osteoarthritis and Neuropathic Pain Symptomology
Joseph Lesnak¹, Michael Zuscik², Michael Dayton², Craig Hogan², Prabil Kaini², Andrew Clauw³, Jennifer Seifert⁴, Michael Clay⁵, Theodore Price¹ and Larry Moreland⁶, ¹University of Texas at Dallas, Dallas, ²University of Colorado School of Medicine, Aurora, ³Univ of Colorado, Aurora, CO, ⁴University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, ⁵University of Colorado, Aurora, CO, ⁶University of Colorado, Denver, CO
Background/Purpose: Osteoarthritis (OA) is a painful disease of the synovial joint and is the most common form of arthritis with a large global burden. A…
Abstract Number: 1134 • ACR Convergence 2025
Efficacy and Safety of Anakinra for Acute Calcium Pyrophosphate Deposition Disease Flare: A Systematic Review and Meta-Analysis
Pannathorn Nakaphan¹, Somkiat Phutinart², Patavee Pajareya², Priabprat Jansem³, Nattanicha Chaisrimaneepan⁴, Pim Jetanalin⁵ and Noppachai Siranart², ¹Department of Internal Medicine, Weiss Memorial Hospital, Chicago, IL, ²Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, ³Department of Psychiatry, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand, ⁴Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, ⁵Department of Medicine, Division of Rheumatology, University of Illinois College of Medicine, Chicago, IL
Background/Purpose: Calcium Pyrophosphate Deposition Disease (CPPD) is a common inflammatory arthritis among older adults. Comorbidities often limit conventional treatment of acute CPPD flare. Anakinra, an…
Abstract Number: 1329 • ACR Convergence 2025
Relationship Between Circulating Bacterial Small RNAs, Methotrexate Response, and Microbiome in New Onset Rheumatoid Arthritis
Carolina Ramirez-Becerra¹, Tulsi Joishy², Sheau-Chiann Chen², Marisol Ramirez-Solano², Quanhu Sheng², Peter Turnbaugh³, Carles Ubeda⁴, Renuka Nayak⁵, Rebecca Blank⁶, Jose Scher⁷ and Michelle Ormseth², ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, ³University of California, San Francisco, San Francisco, CA, ⁴Fisabio, Madrid, ⁵University of California, San Francisco (UCSF), San Francisco, CA, ⁶NYU Langone Health, New York, NY, ⁷New York University School of Medicine, New York, NY
Background/Purpose: Microbiome and microbial products are possible contributors and predictors to methotrexate (MTX) response variability. Bacterial small RNAs (sRNAs) are found in human plasma and…
Abstract Number: 1337 • ACR Convergence 2025
The Association Between Glucagon-Like Peptide-1 Receptor Agonist and Rheumatoid Arthritis: A Population-Based Case Control Study
Ariel Israel¹, Fadi Hassan², Jalal Kurtam², Jamal Awad², Eugene Merzon¹ and Mohammad Naffaa³, ¹Leumit Health Services, Tel-Aviv, Israel, ²Galilee Medical Center, Nahariya, Israel, ³The Azriel's Faculty of Medicine, Bar-Ilan University, Safed, Israel; The Rheumatology Unity, Galilee Medical Center, Naharyia, Israel
Background/Purpose: The increasing use of glucagon-like peptide-1 receptor agonists (GLP1-RAs) for diabetes mellitus (DM) and weight loss has the potential modify the risk for rheumatoid…
Abstract Number: 1254 • ACR Convergence 2025
Symptom Burden and Treatment Experience in Fibromyalgia: Results From a National Patient Survey
Lesley Arnold¹, Zhao Yang², Parul Houston², Todd Grinnell² and Daniel Clauw³, ¹University of Cincinnati College of Medicine, Cincinnati, OH, ²Axsome Therapeutics, Inc, New York, NY, ³Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, MI
Background/Purpose: Fibromyalgia (FM) is a chronic, widespread pain disorder driven by dysregulated central pain processing which substantially impairs daily function and quality of life. Approved…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].